Detail of > 55-06-1
- MSDS Download

- CAS Number:
- 55-06-1
- Name:
Liothyronin sodium
- Superlist Name:
- Liothyronine sodium
- Formula:
- C15H11I3NNaO4
- Molecular Structure:

- Synonyms:
- Alanine,3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]-, monosodium salt, L- (8CI);L-Tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-, monosodium salt (9CI);3,3',5-Triiodo-L-thyronine sodium salt;3,3',5-Triiodothyronine sodium salt;3,5,3'-Triiodo-L-thyronine monosodium salt;Basoprocin;Cynomel;Cyomel;Cytobin;Cytomel;Cytomel sodium;Cytomine;Ibiothyron;L-Triiodothyroninesodium salt;Liothyroniinde sodium salt;Liothyroninesodium;Sodium 3,3',5-triiodo-L-thyronine;Sodium 3,5,3'-triiodothyronine;Sodium L-3,3',5-triiodothyronine;Sodium L-triiodothyronine;Sodium T3;Sodiumliothyronine;Sodium triiodo-L-thyronine;Sodium triiodothyronine;T3 Sodiumsalt;Tertroxin;Triiodothyronine sodium salt;Triostat;Triothyrone;
- Molecular Weight:
- 672.95
- EINECS:
- 200-223-5
- Melting Point:
- 205 °C (dec.)(lit.)
- Boiling Point:
- 563.5 °C at 760 mmHg
- Flash Point:
- 294.6 °C
- Appearance:
- white to beige powder
- Hazard Symbols:
Xn- Risk Codes:
- 20/21/22
- Safety:
- 22-24/25-36Details
Related products
Other Products
- Titanium Dioxide Carbon black Glutathione Adenosine Cable pulling lubricant
- 965-93-5Estra-4,9,11-trien-3-one,17-hydroxy-17-methyl-, (17b)-
- 622-26-44-Piperidineethanol
- 55-06-1Liothyronin sodium
- 13547-70-12-Butanone,1-chloro-3,3-dimethyl-
- 87-78-5Mannitol
- 13708-63-9Terbium fluoride (TbF3)
- 71422-67-8Benzamide,N-[[[3,5-dichloro-4-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]amino]carbonyl]-2,6-difluoro-
- 53-59-8Adenosine5'-(trihydrogen diphosphate), 2'-(dihydrogen phosphate), P'®5'-ester with3-(aminocarbonyl)-1-b-D-ribofuranosylpyridinium, inner salt
- 109244-58-8Benzoic acid,2-(3,6-diamino-9H-xanthen-9-yl)-, methyl ester
- 548-29-82,3-Naphthalenedimethanol,1,2,3,4-tetrahydro-7-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-6-methoxy-,(1S,2R,3R)-
- 936-59-41-Propanone,3-chloro-1-phenyl-
- 24394-09-0Butanoic acid,3,4-dihydroxy-2-methylene-,(3aR,4S,6E,10Z,11aR)-2,3,3a,4,5,8,9,11a-octahydro-10-(hydroxymethyl)-6-methyl-3-methylene-2-oxocyclodeca[b]furan-4-ylester, (3R)-
- 2243-35-8Ethanone,2-(acetyloxy)-1-phenyl-
- 3883-86-11,1'-Biphenyl,2,2',3,3',5,5',6,6'-octafluoro-
- 36614-32-1Prosta-5,8(12),13,17-tetraen-1-oicacid, 15-hydroxy-9-oxo-, (5Z,13E,15S,17Z)-
Refine Suppliers Do you want your product ranking ahead? Know what is 'Top Seller'!
- Supplier Location:
China (Mainland)(19)
United States(1)
- Business Type:
- Importer/Exporter(17)Lab/Research institutions(2)
- Certificates:
- ISO(1) Production License (0)
Please post your buying leads,so that our qualified suppliers
will soon contact you!
*Required Fields
Reference
- Intravenous liothyronine sodium (T3) for myxedema coma - pharmaceutical considerations
- Intravenous liothyronine sodium (T3) for myxedema coma - pharmaceutical considerations. Odgers, Christine L.; Phillips, Patrick J.; Shanks, Gary (Dep. Pharm., Flinders Med. Cent., Bedford 5042, Australia). Aust. J. Hosp. Pharm., 14(4), 181-8 (English) 1984. CODEN: AUHPAI. ISSN: 0310-6810. DOCUMENT TYPE: Journal CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 2 The stability of liothyronine Na (I) [55-06-1] in dil. aq. solns. was studied in static and dynamic infusion systems composed of glass and different plastic materials to det. the feasibility of administering parenteral I by intermittent i.v. infusion over a period of 1-2 h. The effect of H+ concn. and the incorporation of drug carriers into the infusion vehicle on the stability of I was investigated. In the static systems, the I concn. decreased rapidly following addn. of a 20 mg/2 mL soln. to 50-100 mL NaCl solns. of varying pH. The rate of loss decreased with time, and was indicative of adsorption to the plastics, cellulose propionate [9004-48-2], PVC [9002-86-2], and polypropylene [9003-07-0], present in the system. The rate of loss of I was greater in the dynamic systems than the static systems, and the extent of loss was affected by the nature of the various components of the fluid pathway. Minimal losses occurred when more concd. solns. (20 mg I/50 mL) were infused by using polypropylene syringes and min. vol. PVC extension tubes as the components of the infusion system. The loss was further minimized by the addn. of drug carriers to the NaCl vehicle, with minimal loss occurring with 2% wt./vol. albumin.
- Effect of triiodothyronine and methylthiouracil on the activity of some enzymes secondary to metabolism of biogenic amines in synaptosomes of rat brain
- Effect of triiodothyronine and methylthiouracil on the activity of some enzymes secondary to metabolism of biogenic amines in synaptosomes of rat brain. Savitskii, S. Yu.; Kononenko, V. Ya. (Kiev. Nauchno-Issled. Inst. Endokrinol., Kiev, USSR). Farmakol. Toksikol. (Moscow), 41(1), 60-3 (Russian) 1978. CODEN: FATOAO. ISSN: 0014-8318. DOCUMENT TYPE: Journal CA Section: 2 (Hormone Pharmacology) Exptl. hyperthyroidism in rats caused by triiodothyronine Na salt (I Na salt) [55-06-1] (12.5 mg/100 g/day for 15 days, s.c.) was characterized by a decrease in the intensity of decarboxylation of dopa [59-92-7] and 5-hydroxytryptophan [56-69-9] and of oxidative deamination of serotonin [50-67-9] and noradrenaline [51-41-2] in brain synaptosomes. During exptl. hypothyroidism caused by methylthiouracil, DOPA decarboxylation and monoamine deamination were increased but 5-hydroxytryptophan decarboxylation was not affected.
- About us
- |
- Payment
- |
- Contact us
- |
- Links
- |
- Help Center
- |
- Disclaimer
- |
- Add to favorite
- | SiteMap
- |
- Product SiteMap
- |
- Manufacturers
- |
- Suppliers
©2008 LookChem.com,License:ICP NO.:Zhejiang10014259
[Hangzhou]86-571-85317600,85317603,85317620

